Skip to content
Matteo Lambertini, MD PhD· @matteolambe · X·· 21 hours agoScore45

anbenitamab

Body

Oral abstract #BreastCancer session at #ESMO26: very promising data with the bispecific anti-HER2 antibody #anbenitamab plus an experimental taxane #HB1801 as first-line therapy in advanced #HER2+ disease

@OncoAlert @myESMO

54 views · 4 likes · 4 reposts · 0 replies

Conference abstracts
LBA15matched by Proffered paper 2: Breast cancer, early and advanced stage

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org
LBA80matched by Rapid oral 1: Gastrointestinal tumour, upper digestive

Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE

https://esmocongress.esmo.org

Source: Matteo Lambertini, MD PhD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org